share_log

艾美疫苗：自願性公告 - 迭代升級狂犬疫苗產品佈局完成，系列產品研發全面推進

AIM VACCINE: VOLUNTARY ANNOUNCEMENT - COMPLETION OF THE LAYOUT OF ITERATIVE RABIES VACCINE PRODUCTS AND FULLY ADVANCING THE RESEARCH AND DEVELOPMENT OF THE PRODUCT SERIES

香港交易所 ·  Mar 3 18:47
Summary by Moomoo AI
艾美疫苗股份有限公司（「艾美疫苗」）近日宣布，其狂犬病疫苗產品線的迭代升級布局已完成，並且系列產品的研發正在全面推進。作為全球第二大狂犬疫苗供應商，艾美疫苗加速開發了三款主要產品：無血清迭代狂犬疫苗、新型工藝人二倍體狂犬疫苗和mRNA迭代狂犬疫苗。其中，無血清迭代狂犬疫苗已完成III期臨床試驗的現場工作，預計於2024年申報上市。新型工藝人二倍體狂犬疫苗預計於2024年上半年提交臨床試驗預申請。而mRNA迭代狂犬疫苗則是國內首款非新冠mRNA疫苗產品。艾美疫苗的無血清疫苗提高了安全性，降低了不良反應的概率，目前全球市場上尚未有無血清狂犬病疫苗獲批上市。新型工藝人二倍體狂犬病疫苗在產品質量和安全性方面相比國內已上市產品有顯著提高。艾美疫苗已建設完成具備生產能力且滿足國際化標準的相關疫苗車間，並正在進行設備調試和驗證工作，預計將為市場提供更優質、更安全的狂犬病疫苗產品。
艾美疫苗股份有限公司（「艾美疫苗」）近日宣布，其狂犬病疫苗產品線的迭代升級布局已完成，並且系列產品的研發正在全面推進。作為全球第二大狂犬疫苗供應商，艾美疫苗加速開發了三款主要產品：無血清迭代狂犬疫苗、新型工藝人二倍體狂犬疫苗和mRNA迭代狂犬疫苗。其中，無血清迭代狂犬疫苗已完成III期臨床試驗的現場工作，預計於2024年申報上市。新型工藝人二倍體狂犬疫苗預計於2024年上半年提交臨床試驗預申請。而mRNA迭代狂犬疫苗則是國內首款非新冠mRNA疫苗產品。艾美疫苗的無血清疫苗提高了安全性，降低了不良反應的概率，目前全球市場上尚未有無血清狂犬病疫苗獲批上市。新型工藝人二倍體狂犬病疫苗在產品質量和安全性方面相比國內已上市產品有顯著提高。艾美疫苗已建設完成具備生產能力且滿足國際化標準的相關疫苗車間，並正在進行設備調試和驗證工作，預計將為市場提供更優質、更安全的狂犬病疫苗產品。
EMERY VACCINES CO., LTD. (“AMY VACCINES”) RECENTLY ANNOUNCED THAT THE ITERATION UPGRADE OF ITS RABIES VACCINE PRODUCT LINE HAS BEEN COMPLETED AND THE DEVELOPMENT OF THE SERIES IS FULLY PROGRESSING. As the world's second largest provider of rabies vaccines, Amy Vaccines has accelerated the development of three major products: the serum-free iterated rabies vaccine, the novel artisanal bivalent rabies vaccine, and the mRNA iterated rabies vaccine. Among them, the serum-free iterated rabies vaccine has completed its Phase III clinical trial and is expected to go on sale in 2024. A clinical trial pre-application is expected to be submitted for a clinical trial in the first half of 2024 for the novel artisan biogamous rabies vaccine. The mRNA iteration...Show More
EMERY VACCINES CO., LTD. (“AMY VACCINES”) RECENTLY ANNOUNCED THAT THE ITERATION UPGRADE OF ITS RABIES VACCINE PRODUCT LINE HAS BEEN COMPLETED AND THE DEVELOPMENT OF THE SERIES IS FULLY PROGRESSING. As the world's second largest provider of rabies vaccines, Amy Vaccines has accelerated the development of three major products: the serum-free iterated rabies vaccine, the novel artisanal bivalent rabies vaccine, and the mRNA iterated rabies vaccine. Among them, the serum-free iterated rabies vaccine has completed its Phase III clinical trial and is expected to go on sale in 2024. A clinical trial pre-application is expected to be submitted for a clinical trial in the first half of 2024 for the novel artisan biogamous rabies vaccine. The mRNA iteration rabies vaccine is the first non-novel mRNA vaccine product in the country. EME'S SERUM VACCINE IMPROVES SAFETY AND REDUCES THE LIKELIHOOD OF ADVERSE REACTIONS. CURRENTLY, NO ANEMIA RABIES VACCINE HAS BEEN APPROVED ON THE GLOBAL MARKET. Novel artisan bivalent rabies vaccine has improved significantly in terms of product quality and safety compared to domestically marketed products. EME Vaccines has built relevant vaccine workshops that are capable of production and meet international standards, and is conducting equipment commissioning and validation work, which is expected to bring higher quality, safer rabies vaccine products to the market.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more